Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder

Sponsor

BioXcel Therapeutics Inc (Industry)

Overall Status

Recruiting

CT.gov ID

NCT06041646

Collaborator

Lotus Clinical Research, LLC (Other)

Enrollment

Locations

Arm

Anticipated Duration (Months)

Patients Per Site

1.7

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is an in-clinic, single arm, open-label study assessing tachyphylaxis, tolerance, and withdrawal following repeated doses of Igalmi in adult males and females with agitation associated with schizophrenia or bipolar disorder.

Condition or Disease	Intervention/Treatment	Phase
Bipolar Disorder Schizophrenia Agitation,Psychomotor Schizo Affective Disorder Schizophreniform Disorders	Drug: Sublingual film containing Igalmi	Phase 4

Detailed Description

This is an in-clinic, single arm, open-label study assessing tachyphylaxis, tolerance, and withdrawal following repeated doses of Igalmi in adult males and females (18 to 65 years old, inclusive) with agitation associated with schizophrenia or bipolar disorder. Subjects will be screened for eligibility within 15 days of first dose and no study procedures will occur unless subjects provide written informed consent. Subjects will receive single doses of 180 μg of Igalmi as needed for the treatment of agitation over a period of 7 days followed by a 3- day follow-up period during which time no Igalmi will be administered in an effort to characterize any potential withdrawal. Subjects will sublingually self-administer Igalmi for an agitation episode that reaches a pre-dose PEC total score of 14 or greater, as determined by a trained rater. Safety assessments will be conducted before and after each dose. If the subject's agitation is recurrent or persistent, repeat doses of 90 µg may be administered (no more than 2 repeat doses within a 24-hour period) in the absence of any safety concerns or adverse events.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

20 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Intervention Model Description:

Open-LabelOpen-Label

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Characterization of Tachyphylaxis, Tolerance, and Withdrawal After Discontinuation of Igalmi in Frequently Agitated Schizophrenic or Bipolar Patients After 7 Days of PRN Treatment

Anticipated Study Start Date :

Sep 1, 2023

Anticipated Primary Completion Date :

Mar 1, 2024

Anticipated Study Completion Date :

Mar 1, 2024

Arms and Interventions

Arm	Intervention/Treatment
Other: Active Treatment - 180 mcg of Igalmi (dexmedetomidine) An initial dose of 180 µg of Igalmi as needed for the treatment of agitation over a period of 7 days. In the event of persistent or recurrent agitation, investigators may choose to repeat dose at 90 μg after the 2-hour time point in the absence of dose-limiting adverse events or safety concerns. A maximum of 2 repeat doses will be allowed in a 24-hour period.	Drug: Sublingual film containing Igalmi Sublingual film containing 180 µg of Igalmi (dexmedetomidine) Other Names: Dexmedetomidine BXCL501

Arm

Intervention/Treatment

Other: Active Treatment - 180 mcg of Igalmi (dexmedetomidine)

An initial dose of 180 µg of Igalmi as needed for the treatment of agitation over a period of 7 days. In the event of persistent or recurrent agitation, investigators may choose to repeat dose at 90 μg after the 2-hour time point in the absence of dose-limiting adverse events or safety concerns. A maximum of 2 repeat doses will be allowed in a 24-hour period.

Drug: Sublingual film containing Igalmi

Sublingual film containing 180 µg of Igalmi (dexmedetomidine)

Other Names:

Dexmedetomidine

BXCL501

Outcome Measures

Primary Outcome Measures

Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score [Baseline and 2 hours post-dose for all doses administered]
The Positive and Negative Syndrome Scale-Excited Component (PEC) includes 5 items-poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items, the PEC total score, ranges from 5 (absence of agitation) to 35 (extremely severe).
Clinical Global Impression - Improvement (CGI-I) [2 hours post-dose for all doses administered]
The Clinical Global Impression - Improvement (CGI-I) for agitation in response to treatment measures the current level of agitation relative to the level of agitation prior to administration of study intervention. The CGI-I scores range from 1 to 7 with a score of 1 indicating very much improved, and a score of 7 indicating very much worse.

Secondary Outcome Measures

Incidence of Adverse Events During the Follow-up Period [Day 8 through Day 10]
Evaluation of withdrawal phenomenon based on the occurrence of adverse events such as tachycardia, systolic hypertension, nausea, or vomiting and the emergence of any new adverse events on ≥2 consecutive days of the 3-day off-treatment follow-up period.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 65 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Male and female subjects between the ages of 18 to 65 years, inclusive.
Subjects who have met DSM-5 criteria for schizophrenia, schizoaffective, or schizophreniform disorder or bipolar I or II disorder.
Subjects who are currently moderate to severely agitated at least 3 days a week.
Subjects who read, understand, and provide written informed consent.
Subjects who are in good general health prior to study participation as determined by a detailed medical history and in the opinion of the Principal Investigator.
Subjects who agree to use a medically acceptable and effective birth control method
Subjects must be willing to remain in-clinic for the duration of the study.

Exclusion Criteria:

Subjects with agitation caused by acute intoxication, including positive identification of alcohol by breathalyzer or drugs of abuse during screening.
Use of benzodiazepines or other hypnotics or antipsychotic drugs in the 6 hours before study treatment.
Subjects with congenital prolonged QT syndrome.
Prior treatment with Igalmi